SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-047833
Filing Date
2024-04-25
Accepted
2024-04-24 20:42:21
Documents
54
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q vktx-20240331.htm   iXBRL 10-Q 1752016
2 EX-31.1 vktx-ex31_1.htm EX-31.1 15703
3 EX-31.2 vktx-ex31_2.htm EX-31.2 15679
4 EX-32.1 vktx-ex32_1.htm EX-32.1 11775
  Complete submission text file 0000950170-24-047833.txt   7279387

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT vktx-20240331.xsd EX-101.SCH 991660
57 EXTRACTED XBRL INSTANCE DOCUMENT vktx-20240331_htm.xml XML 1242871
Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 858-704-4660
Viking Therapeutics, Inc. (Filer) CIK: 0001607678 (see all company filings)

IRS No.: 461073877 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37355 | Film No.: 24872473
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)